State of Wyoming Has $94,000 Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• The State of Wyoming has reduced its holdings in Gilead Sciences by 86.8%, now owning 842 shares valued at $94,000.
• Insider transactions include Director Jeffrey Bluestone selling 5,000 shares for approximately $548,700, marking a 35.92% decrease in his position.
• Analysts have raised price targets for Gilead Sciences, with ratings now averaging a "Moderate Buy" and a consensus price target of $115.39.

State of Wyoming trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 86.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 842 shares of the biopharmaceutical company's stock after selling 5,542 shares during the period. State of Wyoming's holdings in Gilead Sciences were worth $94,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Nissay Asset Management Corp Japan ADV increased its position in Gilead Sciences by 5.2% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after purchasing an additional 14,009 shares during the last quarter. Golden State Wealth Management LLC increased its position in Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after purchasing an additional 109 shares during the last quarter. Mufg Securities Americas Inc. acquired a new position in Gilead Sciences in the 4th quarter worth about $1,699,000. ASR Vermogensbeheer N.V. acquired a new position in Gilead Sciences in the 1st quarter worth about $11,688,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in Gilead Sciences by 4.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company's stock worth $32,827,000 after purchasing an additional 13,194 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the sale, the director owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the sale, the chief financial officer directly owned 160,110 shares in the company, valued at $18,977,838.30. The trade was a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock worth $9,371,330 over the last 90 days. Insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on GILD. UBS Group upped their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research report on Friday, July 25th. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a report on Tuesday, August 19th. Finally, Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $115.88 on Tuesday. The business has a 50 day moving average price of $113.69 and a 200 day moving average price of $109.95. Gilead Sciences, Inc. has a twelve month low of $78.36 and a twelve month high of $121.83. The company has a market cap of $143.79 billion, a price-to-earnings ratio of 23.08, a PEG ratio of 0.78 and a beta of 0.36. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter in the prior year, the company earned $2.01 EPS. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a dividend of $0.79 per share. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences's dividend payout ratio is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.